Oncotarget is a medical journal that focuses on oncology. The journal publishes peer-reviewed research every week. The research papers are published online and hosted by Impact Journal Publishing. The journal was launched in 2010. It is indexed by various online medical search engines such as PubMed, Scopus and Biosis Previews.The journal is edited by Mikhail Blagosklonny, a renowned scientific researcher associated with Roswell Park Cancer Institute. Andrei Gudkov of the same institute serves as the co-editor-in-chief. In like manner, the list of the members of the editorial board is like a who’s who in oncology. The journal publishes the highest number of research papers on oncology. The journal membership includes numerous award-winning scientists.
The multidisciplinary journal goes beyond oncology. Research paper of Oncotarget in various disciplines such as neuroscience, pathology, microbiology, endocrinology, and cardiology among numerous others. The research papers are open access. Anyone can view them from the portal. It provides effective collaboration between the different disciplines of biomedical science. Oncotarget focuses on maximizing the impact of cancer research. Papers are widely and quickly distributed. Groundbreaking discoveries are shared quickly through the platform. This is achieved by employing an innovative peer-review model. You can submit your research paper quickly and easily through the portal. The review process is quick and efficient. Additionally, it is transparent, credible
The submission guidelines are posted on the portal. This includes tips for authors and reviewers as well as citation formatting instructions. The review process is simple. The author submits the paper and designates any preferred reviewers. The editors assign additional reviewers and allow them to work. After getting the reviewers feedback, the editor communicates the decision to the author. This expedites the review process. Authors normally get feedback within a month.The journal is a trendsetter in the industry. It has been at the forefront of publishing groundbreaking discoveries by renowned scientists. This includes advances in cancer therapy and the aging process, artificial intelligence, and conditions such as leukemia. It was the first to publish studies demonstrating the direct relationship between gum tissue damage and e-cigarettes. This disproves the notion that e-cigarettes are a healthier alternative.
Mikhail Blagosklonny is a competent scientist, lecturer, innovator, and author. Mikhail Blagosklonny lectures oncology at the New York-based Roswell Park Cancer Institute. He studies signal transduction, cellular biology, anticancer therapeutics, cellular senescence, and cell cycle. He has built an exciting career in the field of research.
Education and career history
Blagosklonny attended the First Pavlov State Medical University of St. Petersburg and earned his Master’s degree in internal medicine. Later on, he graduated with a doctorate’s degree in cardiology and experimental medicine from the same university. In 2002, the Valhalla, NY-based New York Medical College appointed him as the associate professor in charge of the medical department. A few months later, Mikhail Blagosklonny landed another distinguished appointment from Ordway Research Institute headquartered in Albany, New York to serve as a senior scientist. He relinquished his position in 2009 and joined Roswell Park Cancer Institute as the oncology’s professor.
Mikhail Blagosklonny is one of the founders of Cell Cycle and serves as its editor-in-chief. He is an associate editor of Cancer Research, Autophagy, American Journal of Pathology, Cell Death & Differentiation, and International Journal of Cancer Research. He was responsible for advancing the research on signal transduction paths from cancer to aging. He also revealed a potential target for lowering the rate of aging and diseases associated with aging.
Read more: Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute
Appointment at Roswell Park Cancer Institute
Roswell Park’s senior VP in charge of basic science, Andrei V. Gudkov, said that Mikhail Blagosklonny is an accomplished researcher who introduced innovative concepts in cancer biology and its treatment. He added that Blagosklonny would assist in developing new anticancer concepts and strategies of cancer treatment and prevention. The researcher will utilize Roswell Park’s ideas and strategies such as preventing radio and chemotherapy from damaging healthy cells, tissue-specific therapy, and averting cancer by lowering the rate of organismal aging, to come up with more efficient cancer treatments.
Apart from leading the fight against cancer, Blagosklonny has been conducting intensive researches on underlying aging mechanisms. His mission is to develop medications that can slow down the rate of aging. Therefore, Blagosklonny has come up with a hypothesis concerning the possibility of using TOR signaling in slowing down aging and cancer therapy. He has proposed the use of rapamycin, a renowned cancer medication, as a potential anti-aging drug. Blagosklonny is recognized across the globe as one of the most passionate supporters of rapamycin in life extension research. He has authored and published over 270 scientific papers with more than 25,000 citations.
Review publishing of Mikhail Blagosklonny on Impact Journals
Read more about Mikhail Blagosklonny on Nature